Everything below concerns reverse-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Novo Nordisk has also developed a genetically engineered insulin independently using a yeast process. According to a survey that the International Diabetes Federation conducted in 2002 on the access to and availability of insulin in its member countries, approximately 70% of the insulin that is currently sold in the world is recombinant, biosynthetic 'human' insulin. A majority of insulin used clinically today is produced this way, although clinical experience has provided conflicting evidence on whether these insulins are any less likely to produce an allergic reaction. Adverse reactions have been reported; these include loss of warning signs that patients may slip into a coma through hypoglycemia, convulsions, memory lapse and loss of concentration. However, the International Diabetes Federation's position statement from 2005 is very clear in stating that "there is NO overwhelming evidence to prefer one species of insulin over another" and "[modern, highly purified] animal insulins remain a perfectly acceptable alternative." Since January 2006, all insulins distributed in the US and some other countries are synthetic "human" insulins or their analogues. A special FDA importation process is required to obtain bovine or porcine derived insulin for use in the US, although there may be some remaining stocks of porcine insulin made by Lilly in 2005 or earlier, and porcine lente insulin is also sold and marketed under the brand name Vetsulin(SM) in the US for veterinary usage in the treatment of companion animals with diabetes.
=== Meat tenderizing and other uses === Along with papain, bromelain is one of the most popular proteases to use for meat tenderizing. Bromelain is sold in a powdered form, which is combined with a marinade, or directly sprinkled on the uncooked meat. Cooked or canned pineapple does not have a tenderizing effect, as the enzymes are heat-labile and denatured in the cooking process. Some prepared meat products, such as meatballs and commercially available marinades, include pineapple or pineapple-derived ingredients. Although the quantity of bromelain in a typical serving of pineapple fruit is probably fairly minimal, specific extraction can yield sufficient quantities for domestic and industrial processing, including uses in baking, anti-browning of cut fruit, textiles and cosmetics manufacturing.
== Scientific background == Platelet-derived growth factor (PDGF) is a signalling protein involved in wound healing, tissue repair, and angiogenesis. Research has established that PDGF stimulates chemotaxis and proliferation in monocytes, macrophages and fibroblasts, playing a key regulatory role in the tissue repair cascade. Studies have further shown that exogenous recombinant PDGF-BB significantly accelerates wound closure in both incisional and excisional wound models. Other growth factors, including transforming growth factor-β, have also been studied in experimental wound-healing models. The only PDGF-based drug currently approved by a major regulatory authority is becaplermin, sold under the brand name Regranex, a recombinant human PDGF-BB gel approved by the U.S. Food and Drug Administration (FDA) in 1997 for the treatment of diabetic neuropathic foot ulcers. As of the date of this article, no PDGF drug has been approved for commercial sale in China.
Outer space has very low density and pressure, and is the closest physical approximation of a perfect vacuum. But no vacuum is truly perfect, not even in interstellar space, where there are still a few hydrogen atoms per cubic meter. Stars, planets, and moons keep their atmospheres by gravitational attraction, and as such, atmospheres have no clearly delineated boundary: the density of atmospheric gas simply decreases with distance from the object. The Earth's atmospheric pressure drops to about 32 millipascals (4.6×10−6 psi) at 100 kilometres (62 mi) of altitude, the Kármán line, which is a common definition of the boundary with outer space. Beyond this line, isotropic gas pressure rapidly becomes insignificant when compared to radiation pressure from the Sun and the dynamic pressure of the solar winds, so the definition of pressure becomes difficult to interpret. The thermosphere in this range has large gradients of pressure, temperature and composition, and varies greatly due to space weather. Astrophysicists prefer to use number density to describe these environments, in units of particles per cubic centimetre. But although it meets the definition of outer space, the atmospheric density within the first few hundred kilometers above the Kármán line is still sufficient to produce significant drag on satellites. Most artificial satellites operate in this region, called low Earth orbit, and must fire their engines every couple of weeks or a few times a year (depending on solar activity).
Neanderthals appear to have lived lives of frequent traumatic injury and recovery, indicating the setting of splints and dressing of major wounds. By and large, they appear to have avoided severe infections, indicating long-term treatment. Their knowledge of medicinal plants was comparable to that of Cro-Magnons. In 2026, a study published in PLOS One described a Neanderthal molar recovered from Chagyrskaya Cave in southwestern Siberia, dating to approximately 59,000 years ago, which bears evidence of an intentional dental procedure. Analysis of the tooth, designated Chagyrskaya 64, revealed a deep hole drilled into the chewing surface using a fine-pointed stone tool, extending into the pulp chamber in a manner consistent with cavity intervention to relieve pain — representing the earliest known instance of dental cavity treatment in human evolutionary history. Subsequent wear on the tooth indicates the individual survived the procedure. Stone tools on various Greek islands could indicate early seafaring through the Mediterranean, employing simple reed boats for one-day crossings, but the evidence for such a big claim is limited.
Sources: en.wikipedia.org
== Properties == Confluentic acid is a member of the class of chemical compounds called depsides. Its IUPAC name is 4-[2-hydroxy-4-methoxy-6-(2-oxoheptyl)benzoyl]oxy-2-methoxy-6-pentylbenzoic acid. The ultraviolet absorbance maxima (λmax) has two peaks at 268 and 304 nm. In the infrared spectrum, significant peaks indicative of the carboxylic acid functional group occur at 1700 cm−1 (C=O stretching in carbonyl groups) and within the broad range of 2600 to 3100 cm−1 (O-H stretching). The broad band at 3100 is due to hydrogen bonding, while the peak at 3500 is the COOH stretching band. Confluentic acid's molecular formula is C28H36O8; it has a molecular mass of 500.57 grams per mole. In its purified form, it exists as crystalline needles with a melting point of 157 °C (315 °F).
=== Chemical descriptor based === In this approach, descriptors quantifying various electronic, geometric, or steric properties of a molecule are computed and used to develop a QSAR. This approach is different from the fragment (or group contribution) approach in that the descriptors are computed for the system as whole rather than from the properties of individual fragments. This approach is different from the 3D-QSAR approach in that the descriptors are computed from scalar quantities (e.g., energies, geometric parameters) rather than from 3D fields. An example of this approach is the QSARs developed for olefin polymerization by half sandwich compounds.
=== 15 January === At least 120 people were killed in an RSF attack on a civilian convoy being escorted by the Sudan Liberation Movement (SLM) and the Gathering of Sudan Liberation Forces (GSLF) near Kabkabiya, North Darfur. Nine people were killed in attacks by the SAF and the RSF on members of the Kanabi community, who mostly originate from Darfur, in Abu Gouta, Gezira State. Fifteen people were killed in an RSF attack on the village of Al-Khizan in Abu Gouta. The Sultan Ali Dinar Palace Museum in El Fasher was shelled by the RSF, causing a fire that heavily damaged the structure and destroyed its contents and furniture.
=== Cancer === In cancer, tumours take over the body's vascularisation processes to supply themselves with blood, helping them grow and spread. Anti-angiogenic therapies are currently used in combination with other therapies for cancer management. Bevacizumab, a monoclonal antibody & VEGF inhibitor is approved for use in cancer treatment.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.